Vivani Medical Q3 net loss $6.8M; adds NPM-115 for weight management

Vivani Medical, Inc.

2023-Q3 EPS reported -$0.39

Net loss of $6.8M in Q3 2023 vs net income of $1.4M in Q3 2022, driven by prior-year bargain purchase gain.
Cash and equivalents $26.2M at Sept 30, 2023; expected to fund operations into early 2025.
Announced NPM-115 (high-dose exenatide implant) for chronic weight management in obese/overweight patients.
FDA clinical hold on NPM-119 FIH study due to CMC requests; also planning FIH study in Australia.
R&D expense $4.4M (+15% YoY); G&A expense $2.7M (+71% YoY) due to merger-related costs.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vivani Medical, Inc. reported financial results for third quarter of 2023.

Period: third quarter of 2023
Result: reported results

Exact text from the filing

today reported financial results for the third quarter of 2023 and provided a business update.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Vivani Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001753926-23-001482

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.